C4 Therapeutics
CCCC
120 hedge funds and large institutions have $117M invested in C4 Therapeutics in 2023 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 44 increasing their positions, 36 reducing their positions, and 17 closing their positions.
2,313% more call options, than puts
Call options by funds: $193K | Put options by funds: $8K
22% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 36
18% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 17
3% more funds holding
Funds holding: 117 → 120 (+3)
3.88% less ownership
Funds ownership: 80.09% → 76.21% (-3.9%)
49% less capital invested
Capital invested by funds: $229M → $117M (-$112M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$7.36M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$3.4M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.95M |
| 4 |
Renaissance Technologies
New York
|
+$1.73M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$16.6M |
| 2 |
State Street
Boston,
Massachusetts
|
-$9.85M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$4.28M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$2.04M |
| 5 |
Rafferty Asset Management
New York
|
-$1.05M |
CCCC Hedge Fund Activity: Q1 2023 in Review
120 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q1 2023, worth a combined $117M — down 49% from $229M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new CCCC positions and 17 closed out — a net gain of 3 holders — while 44 added to existing stakes and 36 trimmed.
The largest buyer was TCG Crossover Management, opening a new position worth an estimated $7.36M. The largest seller was RTW Investments, exiting entirely with an estimated $16.6M sold.
- 120 institutional investors held C4 Therapeutics (CCCC) as of Q1 2023, up from 117 in Q4 2022.
- Funds reported $117M of C4 Therapeutics stock for Q1 2023, down 49% quarter-over-quarter.
- 20 funds opened new C4 Therapeutics positions in Q1 2023 and 17 closed out, a net change of +3 holders.
- The largest C4 Therapeutics buyer in Q1 2023 was TCG Crossover Management, an estimated $7.36M added.
- The largest C4 Therapeutics seller in Q1 2023 was RTW Investments, an estimated $16.6M sold.
Based on aggregated 13F filings for Q1 2023.